BGPT: Paper Review: Prdx1 promotes the loss of primary cilia in esophageal squamous cell carcinoma

Explore by Goal

Quick Explanation Copied

Concise verdict

Chen et al. (BMC Cancer 2020) report that Peroxiredoxin‑1 (Prdx1) promotes disassembly/loss of primary cilia in ESCC (EC9706 cells) via up‑regulation of the NEDD9 (HEF1)–Aurora A–HDAC6 axis; Prdx1 knockdown restores ciliogenesis, reduces invasion in vitro and lowers tumor growth in vivo (n=10 mice/group) — evidence provided by gene‑chip, qRT‑PCR, IF, transwell, western blots and an Aurora‑A inhibitor (Tripolin A) reversal experiment

Long Explanation

Visual-first paper analysis — Prdx1 promotes primary‑cilia loss in ESCC (Chen et al., 2020)

Key quantitative takeaways (from paper)

Prdx1 knockdown in EC9706: Prdx1 mRNA FC ≈ -5.99 (P = 1.04×10⁻⁷) and 512 genes up / 340 down by microarray
Immunofluorescence: percent ciliated cells increased >2× after Prdx1 knockdown; overexpression reduced percent ciliated cells by >3.1×
Transwell invasion: shPrdx1 → ~30% decrease in invaded cells; OE‑Prdx1 → ~32% increase (Fig.2f–g)
Tripolin A (Aurora A inhibitor) reverses OE‑Prdx1 effects on p‑Aurora A, HDAC6, ciliogenesis and invasion (dose/time dependent; used 4.5 μM for 2 h in many assays)
In vivo xenografts (BALB/c nude): n=10 mice/group; Prdx1 knockdown decreased luciferase radiant efficiency ≈25% and reduced tumor volume and weight; increased tumor cell ciliation by acetyl‑α‑tubulin IF in tumor tissue (Fig.6–7)

Figure A — Cellular phenotypes: Ciliation and Invasion (approximate values extracted)

Notes: ciliation and invasion numbers are taken from paper qualitative/fold changes: authors report >2× increase in ciliated cells after shPrdx1 and >3.1× decrease after OE‑Prdx1; invasion reported ~30% decrease with knockdown and ~32% increase with overexpression (plotted as relative % of control). All values are plotted as approximations suitable for visual comparison; see paper for raw means and SEMs

Figure B — In vivo tumor change (approximated)

Interpretation: authors report significant decreases in tumor volume/weight and ≈25% decrease in luciferase radiant efficiency with shPrdx1 relative to shControl in a 23‑day xenograft experiment (n=10/group) (Fig.6). Values plotted are normalized approximations for visual comparison

Mechanistic chain reported

Prdx1 expression positively regulates NEDD9 (HEF1) expression → activates Aurora A (p‑Aurora A) → upregulates HDAC6 → tubulin deacetylation → cilia disassembly (paper shows concordant mRNA/protein changes and pharmacologic reversal)
Tripolin A experiments support that Aurora A activity is necessary for OE‑Prdx1 driven HDAC6 induction and cilia loss (pharmacologic epistasis)

Strengths (evidence‑based)

Multiple orthogonal readouts: gene‑expression microarray (global), qRT‑PCR (selected), protein (WB), functional (IF for cilia, invasion assays), pharmacologic rescue (Tripolin A), and in vivo xenografts — consistent directionality across assays
Pharmacologic reversal (Tripolin A) provides functional support for the role of Aurora A downstream of Prdx1 rather than simple correlation

Limitations, blindspots and critical gaps

Single cell line (EC9706) used for all in vitro work — no replication in independent ESCC lines or patient‑derived cells; limits generality across ESCC genetic backgrounds
shRNA off‑target risk and lack of genetic rescue: authors used shPrdx1 and OE constructs, but no rescue (re‑expression of Prdx1 in knockdown background) to exclude off‑target effects; limited use of multiple independent shRNAs reported
Quantitative data reporting: figures show bar graphs with SEMs but raw n and full statistics (per‑sample values) are limited; microarray used cutoffs |FC|>1.3 for reporting (less stringent than |FC|>2 used elsewhere) and supplementary files needed for reproducibility
Lack of deeper mechanistic dissection: pathway evidence is correlative + pharmacologic; missing direct biochemical links (e.g., does Prdx1 transcriptionally regulate NEDD9, or act via ROS/redox control of signaling proteins?) — alternative mechanisms (ROS‑dependent vs ROS‑independent actions of Prdx1) remain unresolved
In vivo model limited: only subcutaneous EC9706 xenograft in immunodeficient mice; subcutaneous growth does not fully model esophageal tumor microenvironment or metastasis

How confident are the paper's central claims?

The paper provides internally consistent multi‑modal evidence that manipulating Prdx1 levels changes ciliation, invasion and tumor growth in EC9706 models and that these effects are mediated (at least in part) by the NEDD9–Aurora A–HDAC6 axis; confidence for the observed effects in EC9706 is moderate (because of replication across assays and pharmacologic epistasis). However, confidence that Prdx1 is a general regulator of cilia loss across ESCC tumors in patients is limited by single‑cell‑line use and lack of patient/PDX validation (external generalizability unresolved)

Concrete suggestions to improve/validate the claims (short)

Replicate in ≥2 additional ESCC cell lines and in primary patient‑derived ESCC cells or organoids; report per‑replicate raw data and full statistics in supplements.
Use genetic rescue (re‑express Prdx1 in shPrdx1 cells with shRNA‑resistant construct) to exclude off‑target effects.
Probe mechanism: test whether PRDX1 modifies NEDD9 promoter activity (luciferase reporter), or whether ROS modulation mediates the PRDX1→NEDD9/AURKA axis (use catalytically dead mutants, ROS scavengers and redox‑inactive PRDX1 variants).
Orthotopic and/or PDX in vivo models to show effect on invasion/metastasis and microenvironment interactions.

Selected citations from related work (context)

Peroxiredoxin family members (including PRDX1) are multifunctional: they act as peroxidases, redox sensors and scaffolds in other cancers and developmental contexts, sometimes promoting and sometimes suppressing tumor phenotypes depending on tissue and context — so tissue‑specific validation is critical

Paper review metrics (objective/critical)

paper_novelty	8
paper_novelty_explanation	Shows a previously underappreciated role for PRDX1 in controlling primary cilia through the NEDD9–Aurora A–HDAC6 axis in ESCC; novelty is moderately high because cilia loss in cancers is known but linking PRDX1 mechanistically to this axis in ESCC is new.
paper_quality	6
paper_quality_explanation	Good internal consistency and multimodal assays, but constrained by single cell line, limited genetic specificity controls (no rescue), and moderate reporting of raw data; methods are standard and experiments appear well executed but external validation is lacking.
paper_generality	6
paper_generality_explanation	Mechanism (NEDD9–Aurora A–HDAC6) is a broadly relevant cilia‑disassembly pathway, so if PRDX1 regulation generalizes it could be widely important; current work is limited to ESCC/EC9706 so generality remains intermediate.
paper_usefulness	7
paper_usefulness_explanation	Provides a plausible targetable axis (Aurora A/HDAC6) and implicates PRDX1 as an upstream modulator — therapeutically relevant if validated across models; suggests Tripolin A or HDAC6 inhibitors could modulate ciliogenesis/invasion.
paper_reproducibility	6
paper_reproducibility_explanation	Methods are standard and sufficiently described (lentiviral constructs, MOI, antibodies, microarray platform, Tripolin A concentrations), and supplementary tables are available, but raw per‑replicate numbers and broader sample heterogeneity are not fully provided for quick independent reanalysis.
explanatory_depth	8
explanatory_depth_explanation	Paper connects PRDX1 to a defined disassembly cascade (NEDD9→Aurora A→HDAC6) with both expression and activity readouts plus pharmacologic epistasis, giving mechanistic depth within the measured axis though upstream link (how PRDX1 controls NEDD9) remains to be resolved.

How to improve this review (1 sentence)

Add raw per‑sample microarray/WB/IF values, replicate in ≥2 independent ESCC lines and perform genetic rescue (sh‑resistant PRDX1) plus ROS/redox perturbation experiments to distinguish redox‑dependent vs transcriptional regulation of NEDD9.

Key biological insight

If PRDX1 commonly regulates the NEDD9–Aurora A–HDAC6 cilia‑disassembly axis, redox modulators could re‑establish primary cilia in multiple tumors to limit invasion — but tissue context matters because PRDX1 can be pro‑ or anti‑tumor depending on cancer type and wiring of redox signaling

Novel hypotheses (testable)

PRDX1 regulates NEDD9 transcription via redox‑sensitive transcription factors (e.g., NRF2 or AP‑1 family): test by NEDD9 promoter luciferase, redox scavengers, and PRDX1 mutants.
PRDX1 forms a redox‑dependent complex with basal‑body proteins that promotes Aurora A activation locally; test by co‑IP of PRDX1 with NEDD9/Aurora A in fractionated centrosomal preparations and redox perturbation.

Novel experiments (concise, falsifiable)

Rescue experiment: in EC9706 shPrdx1 cells, reintroduce an shRNA‑resistant PRDX1 (WT and catalytically inactive Cys mutant). Endpoints: percent ciliated cells (IF), NEDD9/p‑Aurora A/HDAC6 levels (WB), and invasion. Prediction: WT rescues phenotype; catalytic mutant distinguishes redox enzymatic role.
Cross‑line validation & patient material: repeat key perturbations (knockdown + OE + Tripolin A) in 2 ESCC lines and in freshly dissociated patient ESCC organoids; measure cilia, invasion, and axis proteins. Failure to replicate in other lines/organoids would falsify generality.

Bioinformatics code hint (1 line)

Re‑analyzing the deposited microarray (Supplementary S1) with limma to produce per‑probe volcano plots and ranked GSEA would quantify pathway robustness and is recommended for transparency.

Data source: Chen Q. et al., BMC Cancer 2020 (DOI:10.1186/s12885-020-06898-y). All plotted numerical values are visual approximations extracted from reported fold changes and percent changes in the paper's figures/supplementary files; see original article and Supplementary Tables (S1–S3) for exact raw probe values and full data

Feedback:

Updated: March 18, 2026